Factors in rural community buprenorphine dispensing.
Buprenorphine
Buprenorphine dispensing
Dispensing cap
Medication-assisted treatment
Pharmacy
Rural
Journal
Exploratory research in clinical and social pharmacy
ISSN: 2667-2766
Titre abrégé: Explor Res Clin Soc Pharm
Pays: United States
ID NLM: 9918266300706676
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
08
12
2021
revised:
27
11
2022
accepted:
28
11
2022
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
There are pharmacy-related barriers to the dispensing of buprenorphine for the treatment of opioid use disorders. These include pharmacists' moral objections and mistrust of treatment regimens; the perception of a limit on the amount of buprenorphine able to be ordered and dispensed; stigma and concerns about diversion; and knowledge and communication gaps. To document pharmacy stakeholders' awareness and interpretation of regulatory policies that may impact rural community pharmacists' willingness and ability to dispense buprenorphine. To identify factors that affect rural community pharmacists' willingness and ability to dispense buprenorphine in Appalachian North Carolina. Qualitative analysis and thematic coding of phone interviews with eight pharmacists from several rural North Carolina counties where local health departments recently began prescribing MOUD and four pharmacy industry stakeholders representing knowledge of wholesale distributors and pharmacy education. Three major themes were identified: stigma and misinformation, provider-prescriber communication, and perceived and actual regulatory constraints. A number of respondents indicated a desire to better understand MOUD treatment plans and displayed a misunderstanding of evidence-based treatment guidelines. Stakeholders indicated the importance of pharmacists establishing a relationship with prescribers and described pharmacist preference for dispensing buprenorphine to established patients over new or out-of-area patients. Pharmacist stakeholders and industry/education stakeholders expressed concern over a perceived DEA 'cap' for buprenorphine ordering. This study provides insight on possible approaches to address rural pharmacy-related barriers patients may face when filling buprenorphine prescriptions. There is a demonstrated need for further pharmacist training on evidence-based practices for treating opioid use disorders and ordering limits, as well as a need for increased communication between prescribers and pharmacists.
Sections du résumé
Background
UNASSIGNED
There are pharmacy-related barriers to the dispensing of buprenorphine for the treatment of opioid use disorders. These include pharmacists' moral objections and mistrust of treatment regimens; the perception of a limit on the amount of buprenorphine able to be ordered and dispensed; stigma and concerns about diversion; and knowledge and communication gaps.
Objectives
UNASSIGNED
To document pharmacy stakeholders' awareness and interpretation of regulatory policies that may impact rural community pharmacists' willingness and ability to dispense buprenorphine. To identify factors that affect rural community pharmacists' willingness and ability to dispense buprenorphine in Appalachian North Carolina.
Methods
UNASSIGNED
Qualitative analysis and thematic coding of phone interviews with eight pharmacists from several rural North Carolina counties where local health departments recently began prescribing MOUD and four pharmacy industry stakeholders representing knowledge of wholesale distributors and pharmacy education.
Results
UNASSIGNED
Three major themes were identified: stigma and misinformation, provider-prescriber communication, and perceived and actual regulatory constraints. A number of respondents indicated a desire to better understand MOUD treatment plans and displayed a misunderstanding of evidence-based treatment guidelines. Stakeholders indicated the importance of pharmacists establishing a relationship with prescribers and described pharmacist preference for dispensing buprenorphine to established patients over new or out-of-area patients. Pharmacist stakeholders and industry/education stakeholders expressed concern over a perceived DEA 'cap' for buprenorphine ordering.
Conclusions
UNASSIGNED
This study provides insight on possible approaches to address rural pharmacy-related barriers patients may face when filling buprenorphine prescriptions. There is a demonstrated need for further pharmacist training on evidence-based practices for treating opioid use disorders and ordering limits, as well as a need for increased communication between prescribers and pharmacists.
Identifiants
pubmed: 36703716
doi: 10.1016/j.rcsop.2022.100204
pii: S2667-2766(22)00103-2
pmc: PMC9871294
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100204Informations de copyright
© 2022 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
No conflicts.
Références
Addiction. 2021 Jun;116(6):1505-1511
pubmed: 33140519
Soc Sci Med. 2005 Dec;61(12):2577-87
pubmed: 15955605
J Subst Abuse Treat. 2019 Sep;104:148-157
pubmed: 31370979
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S12-S18.e4
pubmed: 28163027
NCHS Data Brief. 2021 Mar;(403):1-8
pubmed: 33814038
J Addict Med. 2021 Jul-Aug 01;15(4):272-275
pubmed: 33181577
Explor Res Clin Soc Pharm. 2021 Jun 04;2:100029
pubmed: 35481114
J Am Pharm Assoc (2003). 2022 Sep-Oct;62(5):1606-1614
pubmed: 35643625
JAMA Psychiatry. 2019 Mar 1;76(3):229-230
pubmed: 30586140
J Rural Health. 2022 Jan;38(1):87-92
pubmed: 33733547
South Med J. 2022 Aug;115(8):584-592
pubmed: 35922043
J Addict Med. 2019 Jul/Aug;13(4):264-271
pubmed: 30585875
N C Med J. 2022 Jul-Aug;83(4):288-293
pubmed: 35817448
Qual Health Res. 2014 Jun 16;24(7):1006-1017
pubmed: 24970251
Subst Abus. 2019;40(4):476-483
pubmed: 31418645
J Rural Health. 2019 Jan;35(1):113-121
pubmed: 30339720
J Am Pharm Assoc (2003). 2020 May - Jun;60(3S):S20-S28.e4
pubmed: 32094038
Prev Chronic Dis. 2006 Oct;3(4):A113
pubmed: 16978488
Int J Drug Policy. 2020 Nov;85:102701
pubmed: 32223985
Mol Psychiatry. 2019 Dec;24(12):1868-1883
pubmed: 29934549
BMC Fam Pract. 2019 Nov 15;20(1):157
pubmed: 31729957
Subst Use Misuse. 2020;55(3):349-357
pubmed: 31591924
N Engl J Med. 2020 Aug 20;383(8):703-705
pubmed: 32813945
Explor Res Clin Soc Pharm. 2021 Oct 23;4:100082
pubmed: 35479845